Publications by authors named "Helen Barnacle"

Claim this Profile
P
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
Rashmi Mehta, Eleni Pefani, Misba Beerahee, Noushin Brealey, Helen Barnacle

J Clin Pharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.
David A Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore

Am J Respir Crit Care Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Suissa and Ariel: The FULFIL Trial.
David A Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore

Am J Respir Crit Care Med· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".
David A Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore

Am J Respir Crit Care Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
David A Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore

Am J Respir Crit Care Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.
Steven J Pascoe, David A Lipson, Nicholas Locantore, Helen Barnacle, Noushin Brealey

Eur Respir J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Henrik Watz, Helen Barnacle, Benjamin F Hartley, Robert Chan

Lancet Respir Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
David A Lomas, David A Lipson, Bruce E Miller, Lisa Willits, Oliver Keene, Helen Barnacle

J Clin Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis